Rwanda

The Rwanda Food and Drugs Authority (FDA Rwanda), established under Law No. 60/2018 of 22/08/2018 governing food, drugs, cosmetics, and medical devices, serves as the primary national regulatory authority responsible for the evaluation, registration, and post-market surveillance of health products in Rwanda. FDA Rwanda operates under the Ministry of Health and oversees the approval of pharmaceuticals, medical devices, diagnostics, and increasingly digital health solutions. All health products intended for the Rwandan market must undergo a formal registration process, which includes dossier submission, technical evaluation, and, where applicable, site inspection before a product license is granted.

Applicants are required to appoint a locally registered representative or agent to liaise with FDA Rwanda throughout the registration process. Dossiers are generally expected to follow the Common Technical Document (CTD) format, and FDA Rwanda actively participates in regional harmonization initiatives under the East African Community (EAC) and the African Union Development Agency (AUDA-NEPAD), including the African Medicines Regulatory Harmonization (AMRH) programme. Rwanda has also adopted reliance pathways, allowing expedited review based on approvals from stringent regulatory authorities (SRAs) such as the US FDA, EMA, and WHO prequalification, which can significantly reduce review timelines. Recent reforms have focused on strengthening post-market surveillance, introducing electronic submission systems, and aligning national standards with regional and international frameworks to improve regulatory efficiency and product safety oversight.

Public procurement of health products in Rwanda is centrally coordinated through the Ministry of Health (MoH) in collaboration with the Rwanda Medical Supply (RMS) Ltd, a government-owned entity responsible for the warehousing and distribution of medicines, medical devices, and other health commodities to public health facilities nationwide. The Rwanda Public Procurement Authority (RPPA) governs overarching public procurement regulations and ensures compliance with national tendering rules. The Rwanda Biomedical Centre (RBC) plays a key role in forecasting, quantification, and coordination of health commodity needs, particularly for disease-specific programmes. Procurement decisions at the national level are typically centralized, with district and facility-level procurement following approved national lists and framework contracts.

Rwanda benefits substantially from donor-funded procurement channels, with major partners including the Global Fund to Fight AIDS, Tuberculosis and Malaria, USAID through the GHSC-PSM mechanism, Gavi the Vaccine Alliance, UNICEF Supply Division, and the United Nations Population Fund (UNFPA), all of which contribute significantly to the financing and supply of essential health commodities. Products procured through these channels must generally meet international quality standards, including WHO prequalification or SRA approval. Rwanda has expressed policy interest in promoting local and regional manufacturing as part of its broader economic development strategy, aligned with the Africa CDC's Partnerships for African Vaccine Manufacturing (PAVM) framework and the EAC's regional manufacturing agenda, with preferences and incentives for locally manufactured products under active discussion and gradual development.